NASDAQ$PLRX

Pliant Therapeutics Inc · Q4 2026 earnings

Q4 2026 earnings · · After market close · Investor relations

Briefing

Pliant Therapeutics Inc Q4 fiscal 2025: $20.0M net loss, $0.32 loss per share

for the year ended December 31, 2025, filed with the SEC on March 11, 2026 (the “2025 10-K”). (SEC accession 0001746473-26-000090)

  • Net loss: $20.0M
  • Diluted EPS: $-0.32
  • Operating income: $-21.8M

Headline financials

EPS (adj)

-$0.32

No prior period
Net Income

-$20M

No prior period
Operating Income

-$21.8M

No prior period

Revenue & EPS history

Pliant Therapeutics · Revenue · Quarterly

$150M

Q3 2025
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

-1.8%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-4.2%

Avg return

30 days after

36%

9 / 25 earnings

Positive

+12.1%

Q3 2019

Best reaction

-11.7%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+0.8%-4.2%
Q3 2025+3.3%+17.6%-20.9%
Q1 2025-1.5%-2.9%-1.4%
Q4 2024-11.7%+17.4%-5.1%
Q3 2024-4.5%-12.0%-6.4%
Q2 2024-6.5%-9.6%-1.8%
Q1 2024-1.4%-1.2%-13.4%
Q4 2023-7.8%-4.8%-13.4%
Q3 2023-8.0%-12.4%-2.7%
Q2 2023+3.4%-0.9%-9.5%
Q1 2023+4.2%-0.0%+3.0%
Q4 2022-10.9%-9.4%-17.6%
Q3 2022-6.5%-6.7%-14.5%
Q2 2022+11.9%+12.6%+6.2%
Q1 2022-6.8%-1.8%+40.5%
Q4 2021+3.7%-9.9%-26.6%
Q3 2021-4.0%-3.2%-17.9%
Q2 2021-6.5%-12.4%-15.7%
Q1 2021-0.1%-14.7%-3.1%
Q4 2020+4.6%+2.5%-19.9%
Q3 2020+12.1%+9.9%+21.2%
Q3 2019+12.1%+9.9%+21.2%
Q2 2019-8.5%-8.2%-1.2%
Q2 2020-8.5%-8.2%-1.2%
Q4 2019-8.5%-8.2%-1.2%
Q1 2020
Q1 2019
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro